Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

DISEASE CHARACTERISTICS: * Histologically or pathologically confirmed ovarian epithelial carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma * Stage III disease * Meets 1 of the following criteria: * No prior treatment and no more than 6 months since primary surgery * Platinum-sensitive at second-look surgery with no prior cisplatin therapy * Must have been optimally debulked to less than 2-cm residual individual tumor plaques or, if suboptimally debulked at first surgery, had chemical debulking * No mixed Müllerian tumor or borderline ovarian tumor * No Central nervous system (CNS) or brain metastases PATIENT CHARACTERISTICS: * Gynecologic Oncology Group performance status 0-2 * White blood cell count(WBC) ≥ 3,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9 g/dL * Serum bilirubin ≤ 2 times upper limit of normal (ULN) * Aspartate aminotransferase (AST)and alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal * Creatinine clearance ≥ 45 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for 3 months after discontinuation of study drug * No psychological, familial, sociological, or geographical conditions that do not permit medical follow-up or compliance with the study protocol * No unstable or preexisting major medical conditions, except cancer-related abnormalities * No medical life-threatening complications of their malignancies * No known severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, active uncontrolled infection, or HIV) * No serious active uncontrolled infections * No inadequately controlled hypertension (defined as systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg on antihypertensive medications) * No New York Heart Association grade II-IV congestive heart failure * No weight loss between 5 to ≤ 10% within the past 14 days that is not related to ascites or paracentesis * No prior hypertensive crisis or hypertensive encephalopathy * No myocardial infarction, cerebrovascular accident, transient ischemic attack, or unstable angina within the past 6 months * No evidence of uncontrollable nausea * No clinically significant or symptomatic peripheral vascular disease (e.g., aortic aneurysm or aortic dissection) * No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess * No pre-existing clinically significant hearing loss * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, or adequately treated stage I or II cancer from which the patient is in complete remission * No known hypersensitivity to any component of pemetrexed disodium * Able to take folic acid, vitamin B\_12, and dexamethasone according to protocol * No presence of third-space fluid that cannot be controlled by drainage * No inability to comply with study and/or follow-up procedures PRIOR CONCURRENT THERAPY: * See Disease Characteristics * May have received up to 4 courses of carboplatin and paclitaxel IV as neoadjuvant chemotherapy for advanced, unresectable disease * Concurrent low-dose aspirin therapy (i.e., 325 mg/day) allowed * Concurrent ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) with short elimination half-lives allowed provided ≥ 1 of the following criteria is met: * Creatinine clearance (CrCl) \> 80 mL/min (i.e., normal renal function) * CrCl 45-79 mL/min (i.e., mild to moderate renal insufficiency) AND NSAID dosing interrupted for a period of 2 days before, during, and 2 days after administration of pemetrexed disodium * Concurrent NSAIDs or salicylates with long half-lives (e.g., naproxen, piroxicam, diflunisal, or nabumetone) allowed provided NSAID dosing is interrupted for at least 5 days before, during, and 2 days after administration of pemetrexed disodium * No concurrent antineoplastic or antitumor agents not part of the study therapy (i.e., chemotherapy, radiotherapy, immunotherapy, or hormonal anticancer therapy) * No other concurrent investigational agents